Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.

Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.

Hypertension

Hypertrophy, Left Ventricular

Allopurinol

Placebo

University of Dundee, Ninewells Hospital

Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?

Does Allopurinol Regress Left Ventricular Hypertrophy in Patients With Treated Essential Hypertension?

Baseline and repeat CMRI examinations at baseline (+/- 2 weeks) and after the final 12 month (+/- 2 weeks) visit will be performed on a 3T Magnetom scanners (Siemens, Erlangen, Germany) using dedicated phase array cardiac coils.
Analysis will be performed offline (Argus Software, Siemens) by a single blinded observer for the assessment of left ventricular mass. This single observer will analyze all the scans. The reproducibility of the left ventricular mass assessment using MRI will be derived for this observer.
The change LV mass index in participants treated with allopurinol will be compared with placebo.

Flow mediated dilatation (FMD) of the brachial artery will be performed on two visits (baseline and month 12) according to the guide-lines set by the International Brachial Artery Reactivity Task Force. FMD will be expressed as percent change in diameter relative to the baseline diameter at rest. Analysis of all FMDs will be performed on Brachial Analyser software by a single trained investigator. This investigator will be blind to allocated treatments.
. PWA and PWV will be determined in the arm by recording the radial waveforms and radial-carotid waveforms, respectively, at two visits (baseline and month 12) using the Sphygmocor system. The central augmentation index (AIx) will be corrected to a heart rate of 75 beats/min. A single trained investigator who is blind to the allocated treatment will perform the PWA and PWV.

Patient will undergo 24 hour ambulatory BP monitoring after the screening and final visit (12 months) to assess the difference in blood pressure control with allopurinol versus placebo.

Research bloods will be taken at vist 2 (day 0) and visit 7 (12months) and will compare changes between groups.

Baseline and repeat CMRI examinations at baseline (+/- 2 weeks) and after the final 12 month (+/- 2 weeks) visit will be performed on a 3T Magnetom scanners (Siemens, Erlangen, Germany) using dedicated phase array cardiac coils.
Analysis will be performed offline (Argus Software, Siemens) by a single blinded observer for the assessment of ventricular volumes (EDV, ESV, stroke volume), EF, and left ventricular mass. This single observer will analyze all the scans.
The reproducibility of the left ventricular mass assessment using MRI will be derived for this observer.
We will assess left ventricular (LV) mass, LV end systolic volume, LV end diastolic volume and LV ejection fraction in participants treated with allopurinol versus placebo.

Baseline and repeat CMRI examinations at baseline (+/- 2 weeks) and after the final 12 month (+/- 2 weeks) visit will be performed on a 3T Magnetom scanners (Siemens, Erlangen, Germany) using dedicated phase array cardiac coils.
Analysis will be performed offline (Argus Software, Siemens) by a single blinded observer for the assessment of left ventricular mass and scar volume.

essential hypertension/nausea

Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?

Najkompletnija baza ljekovitog bilja potpomognuta znanošću